ABBOTT LABORATORIES — Director's Dealing 2023

Sep 7, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2023-09-01

Reporting Person: Boudreau Philip P (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-09-01	Common shares without par value	A	2620	—	Acquired	18067	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-09-01	Option (right to buy)	$103.18	A	10223	Acquired	2033-08-31	Common Shares (10223)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common shares without par value	349	Indirect

Footnotes

F1: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

F2: Balance in the Abbott Laboratories Stock Retirement Trust as of September 1, 2023.

F3: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 3,407 on September 1, 2024, 3,408 on September 1, 2025, and 3,408 on September 1, 2026.